161 related articles for article (PubMed ID: 37401402)
1. The impact of preoperative waiting time in Stage II-III gastric or gastroesophageal junction cancer: A population-based cohort study.
Yen CC; Yang YH; Ku HY; Hu HM; Lo SS; Chang HC; Chao Y; Chen JS; Wang HP; Wang TE; Bai LY; Wu MS; Yen CJ; Chen LT; Shan YS
Cancer Med; 2023 Aug; 12(16):16906-16917. PubMed ID: 37401402
[TBL] [Abstract][Full Text] [Related]
2. Perioperative chemotherapy vs. neoadjuvant chemoradiation in gastroesophageal junction adenocarcinoma : A population-based evaluation of the Munich Cancer Registry.
Münch S; Habermehl D; Agha A; Belka C; Combs SE; Eckel R; Friess H; Gerbes A; Nüssler NC; Schepp W; Schmid RM; Schmitt W; Schubert-Fritschle G; Weber B; Werner J; Engel J
Strahlenther Onkol; 2018 Feb; 194(2):125-135. PubMed ID: 29071366
[TBL] [Abstract][Full Text] [Related]
3. Time to adjuvant therapy and other variables in localized gastric and gastroesophageal junction (GEJ) cancer (IJGC-D-13-00162).
Ahmed S; Iqbal N; Yadav S; Zaidi A; Ahmed O; Alvi R; Gardner D; Haider K
J Gastrointest Cancer; 2014 Sep; 45(3):284-90. PubMed ID: 24493115
[TBL] [Abstract][Full Text] [Related]
4. Long-Term Survival in Patients with Gastroesophageal Junction Cancer Treated with Preoperative Therapy: Do Thoracic and Abdominal Approaches Differ?
Kneuertz PJ; Hofstetter WL; Chiang YJ; Das P; Blum M; Elimova E; Mansfield P; Ajani J; Badgwell B
Ann Surg Oncol; 2016 Feb; 23(2):626-32. PubMed ID: 26564243
[TBL] [Abstract][Full Text] [Related]
5. [Comparison of the superiority of different TNM staging systems in Siewert III adenocarcinoma of esophagogastric junction].
Lu Y; Xi H; Xie T; Qiu Z; Wang X; Wei B; Chen L
Zhonghua Wei Chang Wai Ke Za Zhi; 2019 Feb; 22(2):143-148. PubMed ID: 30799536
[TBL] [Abstract][Full Text] [Related]
6. [Neoadjuvant chemoradiotherapy combined with surgery versus direct surgery in the treatment of Siewert type II and III adenocarcinomas of the esophagogastric junction: long-term prognostic analysis of a prospective randomized controlled trial].
Tian Y; Wang Q; Wang J; Qiao XY; Zhang J; Lin YC; Li Y; Fan LQ; Yang PG; Zhao Q
Zhonghua Wei Chang Wai Ke Za Zhi; 2021 Feb; 24(2):128-137. PubMed ID: 33508918
[No Abstract] [Full Text] [Related]
7. Can Clinical Stage in the 8
Watanabe H; Hasegawa S; Kumazu Y; Hashimoto I; Komori K; Suematsu H; Kano K; Fujikawa H; Aoyama T; Yamada T; Yukawa N; Yoshikawa T; Rino Y; Saito A; Ogata T; Oshima T
In Vivo; 2023; 37(4):1790-1796. PubMed ID: 37369497
[TBL] [Abstract][Full Text] [Related]
8. Survival outcomes in patients with gastric and gastroesophageal junction adenocarcinomas treated with perioperative chemotherapy with or without preoperative radiotherapy.
Tian S; Jiang R; Madden NA; Ferris MJ; Buchwald ZS; Xu KM; Cardona K; Maithel SK; McDonald MW; Lin JY; Curran WJ; El-Rayes BF; Behera M; Patel PR
Cancer; 2020 Jan; 126(1):37-45. PubMed ID: 31532544
[TBL] [Abstract][Full Text] [Related]
9. Perioperative chemotherapy for resectable gastroesophageal cancer: a single-center experience.
Molina R; Lamarca A; Martínez-Amores B; Gutiérrez A; Blázquez A; López A; Granell J; Álvarez-Mon M
Eur J Surg Oncol; 2013 Aug; 39(8):814-22. PubMed ID: 23755989
[TBL] [Abstract][Full Text] [Related]
10. MAGEA10 expression is a predictive marker of early hepatic recurrence after curative gastrectomy for gastric and gastroesophageal junction cancer.
Fujiya K; Terashima M; Ohshima K; Aizawa D; Sugino T; Serizawa M; Nakamura K; Nagashima T; Hatakeyama K; Urakami K; Akiyama Y; Tsubosa Y; Kitagawa Y; Yamaguchi K
Gastric Cancer; 2021 Mar; 24(2):341-351. PubMed ID: 32965606
[TBL] [Abstract][Full Text] [Related]
11. [Comparison of clinicopathological features and prognosis between adenocarcinoma of esophagogastric junction and adenocarcinoma of gastric antrum].
Zhu Z; Wang Y; Li F; Gao J; Han B; Wang R; Xue Y
Zhonghua Wei Chang Wai Ke Za Zhi; 2019 Feb; 22(2):149-155. PubMed ID: 30799537
[TBL] [Abstract][Full Text] [Related]
12. [Short-term outcomes and long-term quality of life after undergoing radical proximal gastrectomy with esophageal gastric tube anastomosis and total gastrectomy with Roux-en-Y anastomosis for Siewert type II and III adenocarcinoma of the esophagogastric junction: A propensity score matching analysis].
Xu ZW; Zhao K; Hong QQ; Chen YF; Wang HB; Lin HX; Wang TH; Xiao LB; Zhu JT; Yan S; You J
Zhonghua Wei Chang Wai Ke Za Zhi; 2023 Feb; 26(2):181-190. PubMed ID: 36797565
[No Abstract] [Full Text] [Related]
13. Impact of postoperative TNM stages after neoadjuvant therapy on prognosis of adenocarcinoma of the gastro-oesophageal junction tumours.
Thomaschewski M; Hummel R; Petrova E; Knief J; Wellner UF; Keck T; Bausch D
World J Gastroenterol; 2018 Apr; 24(13):1429-1439. PubMed ID: 29632424
[TBL] [Abstract][Full Text] [Related]
14. Surgery in oesophago-gastric cancer with metastatic disease: Treatment, prognosis and preoperative patient selection.
Schmidt T; Alldinger I; Blank S; Klose J; Springfeld C; Dreikhausen L; Weichert W; Grenacher L; Bruckner T; Lordick F; Ulrich A; Büchler MW; Ott K
Eur J Surg Oncol; 2015 Oct; 41(10):1340-7. PubMed ID: 26213358
[TBL] [Abstract][Full Text] [Related]
15. [Survival comparison of Siewert II adenocarcinoma of esophagogastric junction between transthoracic and transabdominal approaches:a joint data analysis of thoracic and gastrointestinal surgery].
Yang S; Yuan Y; Hu H; Li R; Liu K; Zhang W; Yang K; Yang Y; Bai D; Chen X; Zhou Z; Chen L
Zhonghua Wei Chang Wai Ke Za Zhi; 2019 Feb; 22(2):132-142. PubMed ID: 30799535
[TBL] [Abstract][Full Text] [Related]
16. Impact of preoperative wait time on survival in patients with clinical stage II/III gastric cancer.
Furukawa K; Irino T; Makuuchi R; Koseki Y; Nakamura K; Waki Y; Fujiya K; Omori H; Tanizawa Y; Bando E; Kawamura T; Terashima M
Gastric Cancer; 2019 Jul; 22(4):864-872. PubMed ID: 30535877
[TBL] [Abstract][Full Text] [Related]
17. Comparison between gastric and esophageal classification system among adenocarcinomas of esophagogastric junction according to AJCC 8th edition: a retrospective observational study from two high-volume institutions in China.
Liu K; Feng F; Chen XZ; Zhou XY; Zhang JY; Chen XL; Zhang WH; Yang K; Zhang B; Zhang HW; Zhou ZG; Hu JK
Gastric Cancer; 2019 May; 22(3):506-517. PubMed ID: 30390154
[TBL] [Abstract][Full Text] [Related]
18. Mediastinal Nodal Involvement After Neoadjuvant Chemoradiation for Siewert II/III Adenocarcinoma.
Mitchell KG; Ikoma N; Nelson DB; Maru DM; Erasmus JJ; Weston BR; Vaporciyan AA; Antonoff MB; Mehran RJ; Rice DC; Roth JA; Swisher SG; Sepesi B; Walsh GL; Correa AM; Das P; Blum MA; Badgwell BD; Hofstetter WL
Ann Thorac Surg; 2019 Sep; 108(3):845-851. PubMed ID: 31102632
[TBL] [Abstract][Full Text] [Related]
19. Clinical significance of lower perigastric lymph nodes dissection in Siewert type II/III adenocarcinoma of esophagogastric junction: a retrospective propensity score matched study.
Li ZL; Zhao LY; Zhang WH; Liu K; Pang HY; Chen XL; Chen XZ; Yang K; Hu JK
Langenbecks Arch Surg; 2022 May; 407(3):985-998. PubMed ID: 34792614
[TBL] [Abstract][Full Text] [Related]
20. Characteristics and Survival of Gastric Cancer Patients with Pathologic Complete Response to Preoperative Therapy.
Stark AP; Ikoma N; Chiang YJ; Estrella JS; Das P; Minsky BD; Blum MM; Ajani JA; Mansfield P; Badgwell BD
Ann Surg Oncol; 2019 Oct; 26(11):3602-3610. PubMed ID: 31350645
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
